Dyadic International (NASDAQ:DYAI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
Dyadic International Inc (DYAI) Q3 2025 Earnings Report Preview: What To Expect [Yahoo! Finance]